Biogen (BIIB) cash: $3B
Biogen held $3B in cash and cash equivalents on Dec 31, 2025, up 26.7% from $2.4B a year earlier.
From Biogen's filings with the SEC · Read the filing · BIIB stock page
Biogen cash by year
#204 of 4,171 US companies by cash · See the full ranking
| Year ended | Cash | Change |
|---|---|---|
| Dec 31, 2025 | $3B | +27% |
| Dec 31, 2024 | $2.4B | +126% |
| Dec 31, 2023 | $1B | -69% |
| Dec 31, 2022 | $3.4B | +51% |
| Dec 31, 2021 | $2.3B | – |
Cash of similar companies
Companies in the same industry as Biogen, by SEC industry code, with the closest cash. Each name opens the same page for that company.
| Company | Cash, latest year | Year ended |
|---|---|---|
| Amgen | $9.1B | Dec 31, 2025 |
| Gilead Sciences | $7.6B | Dec 31, 2025 |
| Biogen | $3B | Dec 31, 2025 |
| Moderna | $2.6B | Dec 31, 2025 |
| Immunovant | $995M | Dec 31, 2025 |
| Qiagen | $839M | Dec 31, 2025 |
| Recursion Pharmaceuticals | $743M | Dec 31, 2025 |
Questions and answers
What is Biogen's cash?
Biogen held $3B in cash and cash equivalents on Dec 31, 2025, up 26.7% from $2.4B a year earlier.
Numbers as reported in Biogen's annual and quarterly reports to the SEC (XBRL data). A year is the company's fiscal year that falls mostly in that calendar year; balances such as cash and debt are as of the date shown. Data only, not investment advice. Methodology